Beyond efficacy: Insights from the norursodeoxycholic acid phase III trial in metabolic dysfunction-associated steatotic liver disease
World Journal of Hepatology · 27.08.2026 · 18 (8)
DOI: 10.4254/wjh.117543 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 27.08.2026. Verfasst von Ling-Ying Yu und 1 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
The therapeutic landscape for metabolic dysfunction-associated steatotic liver disease (MASLD) is undergoing rapid transformation with recent drug approvals. This editorial contextualizes a recent phase III trial of norursodeoxycholic acid within this dynamic progress. Panuganti et al recently published a study in World Journal of Hepatology , while demonstrating significant alanine aminotransferase normalization and FibroScan-based liver stiffness improvement, the trial’s short duration (24 weeks), reliance on non-invasive endpoints, and absence of histological confirmation underscore persistent challenges in MASLD drug development.
Zitieren
APA
Yu, L., & Zhang, X. (2026). Beyond efficacy: Insights from the norursodeoxycholic acid phase III trial in metabolic dysfunction-associated steatotic liver disease. World Journal of Hepatology, 18(8). https://doi.org/10.4254/wjh.117543
Vancouver
Yu L, Zhang X. Beyond efficacy: Insights from the norursodeoxycholic acid phase III trial in metabolic dysfunction-associated steatotic liver disease. World Journal of Hepatology. 2026;18(8). doi:10.4254/wjh.117543
BibTeX
@article{Yu2026,
author = {Yu, Ling-Ying and Zhang, Xian-Feng},
title = {Beyond efficacy: Insights from the norursodeoxycholic acid phase III trial in metabolic dysfunction-associated steatotic liver disease},
journal = {World Journal of Hepatology},
year = {2026},
volume = {18},
number = {8},
doi = {10.4254/wjh.117543}
}
EUVIMED